Sarepta Therapeutics Stock Fair Value Calculation – Barclays Stands by Overweight Rating and $203 Price Target for Sarepta Therapeutics
🌧️Trending News Sarepta Therapeutics ($NASDAQ:SRPT) is a biopharmaceutical company that focuses on the development and commercialization of innovative treatments for [...]
SAREPTA THERAPEUTICS Receives Mixed Analyst Ratings with 12 Scoreboard Scores
🌥️Trending News Sarepta Therapeutics ($NASDAQ:SRPT) is a biotechnology company that focuses on developing treatments for rare diseases, particularly in the [...]
Sarepta Therapeutics CFO Sells $0.82 Million Worth of Company Shares, Sparks Speculation of Potential Price Increase
☀️Trending News Sarepta Therapeutics ($NASDAQ:SRPT) is a biotechnology company that focuses on the development of innovative treatments for rare diseases. [...]
Sarepta Therapeutics Inc experiences slight market dip, closing at 124.65
🌥️Trending News Sarepta Therapeutics ($NASDAQ:SRPT) Inc, a biotechnology company focused on developing treatments for rare diseases, saw a slight dip [...]
Sarepta Therapeutics Intrinsic Value Calculation – Sarepta Therapeutics Seeks FDA Approval for Expansion of Elevidys Label
☀️Trending News Sarepta Therapeutics ($NASDAQ:SRPT) is a biopharmaceutical company that focuses on the development and commercialization of precision genetic medicines [...]
Citi Gives Sarepta Therapeutics Buy Rating, Favors Risk/Reward for DMD Drug Approval
☀️Trending News Sarepta Therapeutics ($NASDAQ:SRPT) is a biopharmaceutical company dedicated to the discovery and development of precision genetic medicines to [...]
Sarepta Therapeutics Intrinsic Value Calculation – Sarepta Therapeutics Positioned to Lead Accelerated Growth of Duchenne Muscular Dystrophy Treatment Market
☀️Trending News Sarepta Therapeutics ($NASDAQ:SRPT) is a biopharmaceutical company dedicated to developing treatments for rare and serious diseases. The company [...]
Sarepta Therapeutics Reports FY2023 Q2 Earnings Results for Period Ending June 30th 2023
🌥️Earnings Overview On August 2nd 2023, SAREPTA THERAPEUTICS ($NASDAQ:SRPT) released their financial results for the second quarter of FY2023, which [...]
Sarepta Therapeutics Stock Intrinsic Value – Sarepta Therapeutics Reports 11.9% Increase in Revenue for Q2 of FY2023
☀️Earnings Overview SAREPTA THERAPEUTICS ($NASDAQ:SRPT) reported total revenue of USD 261.2 million for the second quarter of FY2023 which ended [...]
Sarepta Therapeutics (SRPT) Making Significant Strides in Biopharmaceutical Industry
☀️Trending News Sarepta Therapeutics ($NASDAQ:SRPT) Inc. (SRPT) is a biopharmaceutical company that has revolutionized the industry with its innovative treatments [...]
